Spurred by the healthcare reform launched by the central government, healthcare has now become the hot destination for domestic and foreign venture capital (VC).

The buzz has been the most active in the bio-pharmaceutical sector which has raised funds to the tune of nearly $130 million in the first half of the year.

The sector accounted for 20 percent of the investment deals signed in China during the same period, according to a report by Zero2IPO, a leading domestic service provider for the venture capital and private equity industry.